News & Events
March 8, 2023
C-Path Welcomes TransPerfect Life SciencesC-Path is proud to welcome TransPerfect Life Sciences as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Comprised of 21 firms that provide electronic data collection technologies and services for capturing patient-reported outcome and other clinical outcome assessment data in clinical trials, eCOA Consortium members collaborate in a pre-competitive environment to support...
February 17, 2023
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD DiagnosisC-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal Degeneration (FTD) diagnosis yesterday. Also known as frontotemporal degeneration, the Association for Frontotemporal Degeneration (AFTD) defines FTD as a group of brain disorders caused by degeneration of the frontal and/or temporal lobes of the...
February 14, 2023
Regulus Therapeutics Joins PKDOCC-Path is excited to announce that Regulus Therapeutics, Inc. has joined the Polycystic Kidney Disease Outcomes Consortium (PKDOC) as a voting member. Regulus Therapeutics is a biotech company working to deliver life changing medicines to patients with orphan kidney diseases. The programs in their pipeline target kidney diseases of high unmet need, including ADPKD. PKDOC brings together diverse stakeholders from...
February 7, 2023
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Joins PKDOCC-Path is excited to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has joined its Polycystic Kidney Disease Outcomes Consortium as a voting member. PKDOC brings together diverse stakeholders from the pharmaceutical industry, academic researchers, foundations, patient advocacy groups, individuals living with PKD, and regulatory agencies from around the world, to develop solutions to accelerate drug development for PKD,...
January 23, 2023
C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common GoalsCritical Path Institute is pleased to announce the recent collaboration agreement between C-Path and Mobilise-D. By combining C-Path’s unique global regulatory expertise and Mobilise-D’s focus on digital assessment of mobility, this mutually beneficial partnership aims to accelerate and improve the impact of these important initiatives that share common goals. The Critical Path for...